RNA Nanomedicines for Individualized Tumor Immunotherapy…
RNA Nanomedicines for Individualized Tumor Immunotherapy…
RNA Nanomedicines for Individualized Tumor Immunotherapy: Translation from Basic Research into Clinical Phase I Trials
Speaker: Dr. Heinrich Haas, Vice President Drug Delivery, BioNTech RNA Pharmaceuticals GmbH, Mainz, (D)
“Late Breaking and Ongoing Trials”
Chair Prof. Dr. Mike Eaton, ETP Nanomedicine, Oxford (UK)
Day 3 Hall Montreal
CLINAM 2015
The European Summit for Clinical Nanomedicine and Targeted Medicine – The Translation to Knowledge Based Medicine
Eighth Conference and Exhibition,
July 1 2015
Immunotherapy News from China
- UPDATE 2-U.S. FDA approves Merck immunotherapy/chemo combo …
- …Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to…
- UPDATE 2-U.S. FDA approves Merck immunotherapy/chemo combo …
- …in Combination With Anti-PD-L1 Cancer Immunotherapy and …
- …Dosed in First-in-Human Clinical Study of Immunotherapy …
- JITC tumor and cancer immunotherapy papers collection
- Welcome to the submission|Journal for ImmunoTherapy of Cancer
- Immunotherapy shows promise for advanced lymphoma: study
- …from the Monotherapy Arm at the Phacilitate Immunotherapy …
- Allergy Immunotherapy Market to exceed US$ 3.33 Bn by 2025 …
Leave a Reply
You must be logged in to post a comment.